NCT07915596Completed
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
This prospective, open-label, randomized clinical study will evaluate the effect of empagliflozin 10 mg daily, added to standard T2DM treatment, on liver fat and hepatic parameters in adults with type 2 diabetes and nonalcoholic fatty liver disease. Two hundred eligible participants will be randomized 1:1 to empagliflozin plus standard therapy or standard therapy alone and followed for 12 weeks. The primary outcome is change in liver fat assessed by liver ultrasonography. Secondary outcomes include changes in ALT, AST, AST/ALT ratio, AP index, APRI, FIB-4, NFS, and BARD scores.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 792 (actual)
- First submitted
- 17 Sept 2026
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- NCT number
- NCT07915596
What you commit to
- Study type: Observational
- Participants enrolled: 792
- From 1 Jan 2023 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes mellitus. History of diabetic ketoacidosis. Significant chronic liver disease other than nonalcoholic fatty liver disease. Decompensated liver disease or cirrhosis. Severe renal impairment or contraindications to empagliflozin. Current use of another SGLT2 inhibitor. Pregnancy or breastfeeding. Known hypersensitivity to empagliflozin. Any condition considered by the investigator to interfere with study participation or outcome assessment.
Who the study is looking for
- Adults aged 18 years or older. Clinically diagnosed type 2 diabetes mellitus. Diagnosis of nonalcoholic fatty liver disease. Stable antidiabetic treatment before study enrollment. Eligible for treatment with empagliflozin. Willingness to participate in the study. Ability to provide written informed consent.
Age in the registry: 18 years to 99 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Medicine Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.